Nektium's botanical ingredient Zynamite granted US patent for brain-enhancing activities
.jpg)
Nektium's botanical ingredient Zynamite granted US patent for brain enhancing activities. (PRNewsfoto/Nektium)
Zynamite is an all-natural evidence-based nootropic and sports performance ingredient, supported by clinical studies.
The United States Patent and Trademark Office has granted Nektium, a research-based branded botanical ingredient manufacturer based in Spain, a patent for its Compositions for Enhancing Brain Activity.
This patent is part of the intellectual property portfolio supporting Nektium's innovative ingredient Zynamite, a caffeine-free botanical ingredient for mental and physical energy. Zynamite is a sustainable, proprietary standardized extract of leaves of a selection of Mangifera indica, the mango tree.
The caffeine-free and doping-free nootropic activities of Zynamite have been appearing in diverse finished product innovations including popular smart supplements and egaming formulations in Japan.
Recognising the fundamental importance of the mind in sports performance, Nektium applied the brain-activating activities of Zynamite to sports formulations, which have been subjected to four double-blind, randomised controlled clinical trials. The positive results of these sports performance and recovery studies have been published in four peer-reviewed papers.
"The currency of the nutraceutical ingredient industry is scientific evidence obtained from double-blind, randomised controlled clinical studies conducted by reputable academic departments and CROs, and published in leading peer-reviewed journals. Nektium has made a major investment in the clinical research backing Zynamite and continues to invest in ongoing clinical studies," said Dr Nigel Gericke, Nektium's Director of Science. "Our intention is to keep building the clinical research base and intellectual property supporting Zynamite as a premium branded ingredient."
Zynamite was first launched at Vitafoods in Geneva and HI Japan in Tokyo in 2018 and at Supply Side West in the USA in 2019.
The nutraceutical industry has already recognized the clinical research and innovation behind Zynamite awarding the ingredient five awards in the last 2 years: the Nutraingredients Award for sports ingredient of the year in 2018, the Nutraingredients Award for research in 2019, the Frost & Sullivan Award for innovation in 2019, and the European Specialised Sports Nutrition Awards for the 2019 best 'free from' ingredient, and the 2019 runner up award for game-changer ingredient of the year.
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz.
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance